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Molecular Cardiology
Impaired Autonomic Regulation of Resistance Arteries in
Mice With Low Vascular Endothelial Growth Factor or
Upon Vascular Endothelial Growth Factor Trap Delivery
Erik Storkebaum, PhD*; Carmen Ruiz de Almodovar, PhD*; Merlijn Meens, MS;
Serena Zacchigna, PhD; Massimiliano Mazzone, PhD; Greet Vanhoutte, PhD;
Stefan Vinckier, PhD; Katarzyna Miskiewicz, PhD; Koen Poesen, PhD; Diether Lambrechts, PhD;
Ger M.J. Janssen, BSc; Gregorio E. Fazzi, BSc; Patrik Verstreken, PhD; Jody Haigh, PhD;
Paul M. Schiffers, PhD; Hermann Rohrer, PhD; Annemie Van der Linden, PhD;
Jo G.R. De Mey, PhD; Peter Carmeliet, MD, PhD
Background—Control of peripheral resistance arteries by autonomic nerves is essential for the regulation of blood flow. The
signals responsible for the maintenance of vascular neuroeffector mechanisms in the adult, however, remain largely unknown.
Methods and Results—Here, we report that VEGF/ mice with low vascular endothelial growth factor (VEGF) levels
suffer defects in the regulation of resistance arteries. These defects are due to dysfunction and structural remodeling of
the neuroeffector junction, the equivalent of a synapse between autonomic nerve endings and vascular smooth muscle
cells, and to an impaired contractile smooth muscle cell phenotype. Notably, short-term delivery of a VEGF inhibitor
to healthy mice also resulted in functional and structural defects of neuroeffector junctions.
Conclusions—These findings uncover a novel role for VEGF in the maintenance of arterial neuroeffector function and may help
us better understand how VEGF inhibitors cause vascular regulation defects in cancer patients. (Circulation. 2010;122:273-281.)
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Several cues have been identified that control the devel-opment of the sympathetic nervous system,1 but the
molecular mechanisms underlying the maintenance of auto-
nomic innervation of peripheral resistance arteries in adult-
hood remain largely unknown. Periarterial nerves do not
penetrate the medial vascular smooth muscle cell (SMC)
layer but are confined to the media adventitia border. The
varicose terminal portions of these nerve fibers release
transmitter en passage,2 and autonomic neuroeffector junc-
tions (NEJs) in resistance arteries are “atypical” in that they
contain prejunctional membrane thickenings with synaptic
vesicles but lack specialized postjunctional structures.2
Clinical Perspective on p 281
By releasing neurotransmitters, autonomic nerves control the
blood supply to organs. For instance, autonomic control of
resistance arteries mediates thermoregulation in the skin and
redistribution of flow from internal organs to the brain in stress
conditions.3,4 Dysfunction of the periarterial autonomic nervous
control can lead to hypertension, Raynaud phenomenon, and
orthostatic hypotension.5 Impaired vascular regulation has also
been implicated in the hand-foot syndrome in cancer patients
receiving vascular endothelial growth factor (VEGF) inhibitors.6
This syndrome is characterized by dysesthesia, erythema, and
tingling of extremities, which may progress to burning pain with
dryness, cracking, and ulceration of the skin.7,8 The molecular
basis of this syndrome remains largely enigmatic.
VEGF, a key regulator of angiogenesis in health and disease,9
also has neurotrophic effects. VEGF stimulates axon outgrowth
and survival of neurons in vitro,10 and low VEGF levels in
VEGF/ mice, engineered to lack the hypoxia-response element
in the VEGF promoter, cause adult-onset motoneuron degener-
ation, reminiscent of the human motoneuron degenerative dis-
order amyotrophic lateral sclerosis.11 However, surprisingly
little is known about the effects of VEGF on peripheral auto-
nomic nerves and, in particular, about its possible role in the
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autonomic innervation of resistance arteries in vivo. In vitro
studies show that VEGF stimulates axon outgrowth and survival
of superior cervical ganglia12,13 and induces growth cone spread-
ing of cultured postganglionic neurons.14 Furthermore, VEGF
promotes the reinnervation of denervated femoral arteries in
vivo.14 However, a role for VEGF in the maintenance of the
perivascular autonomic nerve plexus in vivo has not been
addressed. Here, we assessed whether VEGF might modulate
the autonomic nervous control of resistance arteries.
Methods
Transgenic Mice and Soluble Flk1 Gene Transfer
VEGF/, VEGF-LacZ, and Flt1-LacZ mice were described previ-
ously.11,15,16 Expression of the soluble extracellular domain of Flk1
(sFlk1) in the circulation was obtained by hydroporating mice with 2.5
mL Ringer solution (150 mmol/L NaCl, 4 mmol/L KCl, 1 mmol/L
CaCl2) containing 50 g per mouse of a vector encoding sFlk1 or an
empty vector as control.17 After 5 days, plasma protein levels of sFlk1
were determined with a soluble VEGF receptor-2 (VEGFR-2)–specific
immunoassay (R&D Systems, Minneapolis, Minn).
Histology and Immunohistochemistry
Perfusion-fixed arteries were embedded in paraffin, and sections
were stained with the following antibodies: polyclonal rabbit anti-
smoothelin antibody (1:100; a gift from G. van Eys, Maastricht
University), anti-desmin antibody (1:50; Cappel, Durham, NC), and
anti–SM myosin heavy chain (MHC) antibody (1:400; ab683,
Abcam, Cambridge, UK). Procedures used for whole-mount staining
of arteries, analysis of skin vascular density, LacZ enzymatic
staining, alkaline phosphatase staining, glyoxylic acid staining, and
noradrenaline content determination are described in the Methods
section of the online-only Data Supplement.
Isometric Wire Myography
Isometric wire myography was performed as described previously.18
Detailed procedures can be found in the Methods section of the
online-only Data Supplement.
Quantitative Real-Time Polymerase Chain
Reaction Experiments
Messenger RNA transcript levels were quantified and normalized
relative to the expression level of -actin or GAPDH with the use of
premade primers and probes (TaqMan Gene Expression Assays, Ap-
plied Biosystems, Foster City, Calif). Relative gene expression in VEGF/
versus control arteries was calculated with the 2CT method.
Transmission Electron Microscopy
Standard procedures were used for transmission electron micros-
copy. Detailed procedures can be found in the Methods section of the
online-only Data Supplement.
Thermoregulation Experiments
A rectal probe connected with a digital thermometer (Physitemp
Instruments) was used to measure body temperature in an ambient
temperature of 21°C on 3 consecutive days with 3 measurements per
day; the average temperature was recorded as baseline. During
exposure to cold stress (8°C for VEGF/ mice, 4°C for sFlk1 mice),
rectal temperature was measured at half-hour intervals for 4.5 hours.
Blood Flow Measurements
Details on these and other methods used in this study can be found in
Methods section of the online-only Data Supplement.
Statistics
For comparison of 2 genotypes or treatment groups, the unpaired
Student t test was used. When data were not normally distributed, the
Mann–Whitney test was used; medians and interquartile ranges are
reported. For the evaluation of body temperature evolution during
cold stress experiments, repeated-measures ANOVA was used. For
statistical analysis of concentration-response curves, ANOVA was
used with Bonferroni correction for multiple testing. A limitation of
our study is that, because of the limited availability of transgenic
mice, sample size in our experiments is often small, increasing the
risk for a type I error.
Results
Expression of VEGF and VEGFRs
For VEGF to regulate the function of resistance arteries, VEGF
and VEGFRs should be expressed in these arteries. We therefore
determined the spatial expression pattern of VEGF and VEGFRs
(VEGFR-1/Flt1 and VEGFR-2/Flk1) in mesenteric and saphe-
nous arteries. In VEGF-LacZ mice, which express nuclear LacZ
under the control of the endogenous VEGF promotor,15 X-gal
staining revealed VEGF expression by medial SMCs (Figure
1A) and by neurons in celiac and superior cervical ganglia
(Figure 1B and not shown), implying that VEGF may also be
released from nerve terminals. X-gal staining of arterial cross
sections of Flt1-LacZ mice, which express cytosolic LacZ under
the control of the endogenous Flt1 promotor,16 revealed Flt1
expression in medial SMCs (Figure 1C). This expression pattern
of Flt1 was confirmed by a VEGF-B186-alkaline phosphatase
(AP) fusion protein, which selectively binds to Flt1 (Figure 1D).
Staining of whole-mount arteries with a VEGF-AP fusion
protein, which binds to Flk1, Flt1, and neuropilin, revealed
expression of VEGFRs also on periarterial nerves (Figure 1E),
and immunostaining for Flt1 or Flk1 labeled perivascular nerve
fibers and endings (Figure 1F and 1G). Thus, VEGF and
VEGFRs are expressed in resistance arteries and periarterial
nerves. We therefore tested whether VEGF might play a role in
vascular regulation of peripheral resistance arteries.
To explore whether VEGF affected vascular regulation, we
used VEGF/ mice, which express reduced VEGF levels.11
ELISA confirmed that VEGF protein levels were reduced in
VEGF/ arteries and ganglia (note I in the online-only Data
Supplement), and immunostaining and quantitative polymer-
ase chain reaction revealed that VEGF expression was re-
duced in arterial SM and postganglionic neurons (Figure I
and note I of the online-only Data Supplement). Because
VEGF/ mice develop motoneuron degeneration beyond 5 to
7 months of age,11 we used only presymptomatic VEGF/
mice (3 months of age) for all experiments.
Impaired Vasoconstrictor Responses of VEGF/
Resistance Arteries Ex Vivo
We then explored by isometric wire myography ex vivo whether
the reduced VEGF levels in VEGF/ mice impaired vascular
regulation of isolated small muscular arteries (mesenteric and
saphenous arteries) and large elastic arteries (common carotid
artery).18 To study whether VEGF modulates vasoregulatory
responses of SMCs, we induced vasoconstriction by exposing
arteries to stimuli that have direct effects on SMCs through
distinct signal transduction pathways, ie, high potassium (K),
angiotensin II, noradrenaline, or the thromboxane A2 analog
U46619. Because the contractile response of an artery depends
on the intrinsic SMC properties but also on the thickness of the
SMC layer (and because VEGF/ arteries were generally
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smaller; Table I of the online-only Data Supplement), we not
only measured active wall tension (N/m), defined as the force
generated by the artery divided by the arterial segment length,
but also calculated active wall stress (N/m2), a parameter of
intrinsic SMC function, by correcting active wall tension for
media thickness.
Compared with wild-type (WT) mice, contractile responses
of resistance arteries to high K, angiotensin II, noradrena-
line, or U46619 were reduced in VEGF/ mice, whereas the
sensitivity to these stimuli was not modified (Figure 2A, 2C,
and 2D, plus Table II and Figure I of the online-only Data
Supplement). Both wall tension and wall stress were reduced
by 50% in VEGF/ mice (Table II of the online-only Data
Supplement). The fact that arterial contractility was impaired
regardless of the type of vasoconstrictor stimulus indicates
that SMCs were generally dysfunctional rather than having a
selective defect in a particular signaling pathway. In addition,
because the contractile responses were also impaired in the
presence of the nitric oxide synthase inhibitor nitro-L-arginine,
the defect was not attributable to abnormal production of nitric
oxide (not shown). Notably, the contractile response of the
elastic carotid arteries was normal (Table II and Figure IA and
ID of the online-only Data Supplement and Figure 2B), indicat-
ing that vascular regulation by densely innervated muscular
arteries, but not by sparsely innervated elastic arteries, is
impaired in VEGF/ mice. Vascular SMC dysfunction was
not accompanied by endothelial cell dysfunction because
endothelium-dependent relaxation induced by acetylcho-
line was normal in resistance arteries of VEGF/ mice
(Figure II of the online-only Data Supplement).
Dedifferentiation of Vascular SMCs in VEGF/
Resistance Arteries
To characterize SMC dysfunction in VEGF/ arteries in
more detail, we measured by quantitative polymerase chain
reaction the expression of “early” and “late” SMC differen-
tiation markers, which are important for establishing SMC
contractile properties in a developmentally sequential order.19
At 3 weeks of age, ie, when the autonomic innervation of
resistance arteries was just established,20 expression of early
(nonmuscle MHC, desmin, and calponin) and late (SM MHC
and smoothelin-B) SMC differentiation markers was compa-
rable in WT and VEGF/ saphenous arteries (Table 1). In
contrast, by 3 months of age, expression of early SMC
Figure 1. Expression pattern of VEGF
and VEGFRs in peripheral resistance
arteries. A and B, X-gal staining on
saphenous arteries (A) and celiac ganglia
(B) of VEGF-LacZ mice revealed VEGF
expression in medial SMCs (A) (arrows,
nuclear LacZ staining) and postgangli-
onic neurons (B). C, X-gal staining on
saphenous arteries of Flt1-LacZ mice
revealed Flt1 expression in medial
SMCs. D, Expression of Flt1 in medial
SMCs was also confirmed with VEGF-
B186-AP fusion protein. E, Staining of
whole-mount arteries with VEGF164-AP
fusion protein revealed expression of
VEGFRs on periarterial nerves (arrows).
F and G, Immunostaining for Flk1 (F) and
Flt1 (G) on whole-mount arteries
revealed expression of Flk1 and Flt1 in
periarterial nerves (arrows). Scale
bar50 m.
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markers was normal, but expression of the late SMC markers
was reduced in VEGF/ saphenous arteries (Table 1).
These results were confirmed by immunostaining (Figure
III of the online-only Data Supplement). No differences were
found in the expression of SMC differentiation markers in
common carotid arteries (Table 1). The reduced expression of
late SMC differentiation markers in VEGF/ arteries can
explain their generally impaired contractile properties. This
defect appeared to be specific for the contractile machinery
because expression of postjunctional neurotransmitter recep-
tors (1-adrenoreceptors, purinergic receptor P2X1, and
NPY1 receptor) and neurotrophic factors (nerve growth fac-
tor, artemin, and neurotrophin-3) was not significantly altered
in VEGF/ arteries (not shown). Thus, SMCs in innervated
resistance arteries differentiate normally during postnatal
development but later dedifferentiate in VEGF/ mice.
Neuroeffector Dysfunction in VEGF/ Arteries
Because vascular regulation was impaired in densely innervated,
but not in sparsely innervated, arteries in VEGF/ mice, sug-
gesting a possible dysfunction of perivascular nerves, we studied
neuroeffector function by ex vivo myography. In mesenteric
arteries of WT mice, electric field stimulation (EFS) or admin-
istration of the indirectly acting sympathomimetic tyramine
induced a strong vasoconstrictor response (Figure 3A and 3B).
In contrast, the contractile response was severely impaired in
VEGF/ arteries (Figure 3A and 3B). To exclude that the
impaired response to these neurogenic stimuli in VEGF/ mice
reflected only intrinsic SMC (and not neuronal) defects, we
expressed the responses as a fraction of the maximal response to
exogenously applied noradrenaline. Even after normalization,
the contractile response remained lower in VEGF/ mice
(Figure 3C and 3D and Table 2), indicating that sympathetic
neuroeffector regulation was dysfunctional.
Because high K induces vasoconstriction via effects on
SMCs and nerve terminals, the neuronal contribution to this
response can be evaluated by measuring the relaxation
induced by blocking postjunctional -adrenoreceptors by
phentolamine. The phentolamine-induced relaxation of the
contractile response to K was smaller in VEGF/ arteries
(Table 2), suggesting that less noradrenaline reached and
activated postjunctional -adrenoreceptors. Overall, besides
general SMC hyporesponsiveness, control of vasomotor tone
by sympathetic nerves was defective in VEGF/ arteries.
Vasorelaxation by afferent sensory-motor nerves18 was also
impaired in VEGF/ arteries (Figure 3E), indicating that
dysfunction of neuroeffector mechanisms involves both sym-
pathetic and sensory-motor nerves.
Cellular Mechanisms of Neuroeffector Dysfunction
in VEGF/ Mice
We then sought to explore the underlying mechanisms of the
perivascular nerve dysfunction. Whole-mount staining for ty-
rosine hydroxylase, noradrenaline, or calcitonin-gene related
peptide revealed that the neuroeffector dysfunction was not
attributable to a reduced density of the periarterial nervous
plexus (Figure IV of the online-only Data Supplement). Addi-
tionally, the noradrenaline content of VEGF/ resistance arteries
was not different from that of controls (Table III of the
online-only Data Supplement). We further analyzed by myogra-
phy the effect of cocaine on the arterial response to exogenous
noradrenaline to assess how efficiently noradrenaline reuptake
by nerve terminals in situ occurred. Indeed, if noradrenaline
uptake is important, blockade of this process by cocaine should
leave more neurotransmitter available to activate postjunctional
Figure 2. Impaired vascular regulation of peripheral resistance
arteries in VEGF/ mice. A and B, Typical recording of contractile
responses to increasing concentrations of the vasoconstrictor
U46619 in mesenteric resistance arteries (A) and carotid arteries (B)
of WT and VEGF/ mice. C and D, Concentration-response curve
of WT and VEGF/ saphenous arteries in response to noradrena-
line (C) and U46619 (D). *P0.05 vs WT.
Table 1. Relative Expression Levels of SMC
Differentiation Markers
Age Artery Target Gene WT VEGF/
3 wk SA Nonmuscle MHC 10014.1 78.719.8
Desmin 10014.7 71.413.1
Calponin 10013.5 63.818.3
SM-MHC 10014.1 78.619.8
Smoothelin 10019.3 118.435.7
3 wk cCA Nonmuscle MHC 10035.4 67.426.9
Desmin 10047.3 156.555.2
Calponin 10044.1 108.759.8
SM-MHC 10035.6 67.326.7
Smoothelin 10037.0 63.022.3
3 mo SA Nonmuscle MHC 10016.3 109.119.7
Desmin 10017.9 84.611.7
Calponin 1008.8 75.812.4
SM-MHC 10018.5 51.09.4*
Smoothelin 10014.2 49.29.8*
3 mo cCA Desmin 1008.8 143.526.4
Calponin 10010.1 86.523.2
SM-MHC 10014.6 117.627.2
Smoothelin 10045.2 96.029.5
SA indicates saphenous artery; cCA, common carotid artery. Relative
expression levels as percentage of WTSEM are shown.
*P0.05 versus WT.
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receptors at the NEJ. Notably, cocaine enhanced the sensitivity
of VEGF/ arteries to noradrenaline, but much less than that of
WT arteries (Table 2). Hyporesponsiveness to cocaine in this
experimental condition might reflect impaired noradrenaline
uptake per se but also could be due to a wider junctional cleft
between nerve varicosities and SMCs because local neurotrans-
mitter concentrations can be influenced more readily by uptake
processes in narrow junctional clefts. To discriminate between
these possibilities, we measured the neuronal uptake of nor-
adrenaline directly. Notably, no differences in noradrenaline
uptake between VEGF/ and WT arteries were found (note II in
the online-only Data Supplement).
We therefore explored whether the junctional cleft between
perivascular nerve varicosities and target vascular SMCs might
be wider. To identify structural abnormalities of VEGF/ NEJs,
transmission electron microscopy was used (Table 3 and Figure
3F and 3G). Morphometric quantification revealed that the
distance between varicosities and the nearest SMC was larger in
VEGF/ arteries (Table 3). Furthermore, varicosities were
smaller and contained fewer mitochondria, and axon bundles
contained fewer varicosities in VEGF/ arteries, whereas the
density of transmitter storage vesicles was not altered (Table 3).
Thus, neuroeffector dysfunction in VEGF/ arteries was accom-
panied by structural changes in NEJs in 3-month-old mice.
To assess whether these structural changes occurred during
development or only after formation of the adult periarterial
nervous network, we repeated the ultrastructural analysis on
arteries of 3-week-old mice in which the periarterial nerve
plexus had just matured.20 Even at this stage, the average
distance between nerve varicosities and SMCs was increased in
VEGF/ arteries, whereas the varicosity area, number of mito-
chondria per varicosity, and number of varicosities per nerve
bundle were reduced in VEGF/ arteries (Table 3). Thus, low
VEGF levels in VEGF/ mice perturb normal development of
arterial NEJs.
Figure 3. Neuroeffector dysfunction in VEGF/ arteries. A and B, Active wall tension in response to EFS (A) and tyramine (B) of WT and
VEGF/ arteries. C and D, Even when normalized to the maximal response to noradrenaline (NA), contractile responses to EFS (C) and
tyramine (D) were reduced in VEGF/ arteries. E, To monitor sensory motor nerve function, we recorded the relaxing responses to cap-
saicin (0.1 and 1.0 mol/L), which selectively stimulates neurotransmitter release from sensory-motor nerve endings, in mesenteric
resistance arteries that were first contracted by U46619. Capsaicin caused a substantial vasorelaxation in WT arteries, but its relaxing
activity was markedly impaired in VEGF/ mice (E). The sensitivity of VEGF/ arteries to exogenous CGRP was not reduced (not
shown), indicating that the vasorelaxation defect was attributable to sensory-motor nerve dysfunction. F and G, Representative trans-
mission electron microscopy pictures of NEJs in VEGF/ (G) and control (F) arteries illustrating wider junctional clefts and fewer mito-
chondria per varicosity in VEGF/ arteries. Dotted lines delineate axon bundles (blue), a varicosity (white), and SMCs (red). The junc-
tional cleft width is indicated by an arrow. c Indicates collagen; el, external elastic lamina; m, mitochondria; and sm, SMC. Scale
bar0.5 m. *P0.05 vs WT.
Table 2. Sympathetic Neuroeffector Function in
Saphenous Arteries
Index Unit WT VEGF/
EFS Emax/Emax-(NA) 0.9470.108 0.4790.129*
Tyramine Emax/Emax-(NA) 0.7120.036 0.3260.089*
Cocaine pD2 NA 0.4900.077 0.1000.230*
Phentolamine % Relaxation of
contractile response to 125
mmol/L K
13.81.7 6.46.3*
NA indicates exogenously applied NA; Emax, maximal response; pD2,log M
EC50 (EC50 is concentration resulting in 50% of Emax); and pD2, increase in
sensitivity resulting from blockade of neuronal uptake. The data represent
meanSEM of 5 measurements.
*P0.05 versus WT.
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Impaired Vascular Regulation of Resistance
Arteries in VEGF/ Mice In Vivo
To assess whether the aforementioned ex vivo changes in
neuroeffector function also impaired autonomic nervous con-
trol of peripheral resistance arteries in vivo, we explored
whether thermoregulation, known to rely on autonomic ner-
vous control of resistance arteries in the skin,3 was impaired
in VEGF/ mice. In baseline conditions, the core body
temperature was 38.20.1°C in adult WT mice but only
37.20.2°C in VEGF/ mice (n8; P0.005). When ex-
posed to cold stress (8°C), VEGF/ mice were unable to
maintain their body temperature and progressively cooled
down to 34.21.1°C after 4.5 hours (n8; P0.002; Figure
4A). This thermoregulatory defect was not attributable to
genotypic differences in blood pressure or heart rate (Table
IV of the online-only Data Supplement), thyroid function
(note III of the online-only Data Supplement), cutaneous
vascular density (percent of surface area covered by vascu-
lature: 29.31.4 in WT mice versus 29.71.0 in VEGF/
mice; n3; P0.83), skeletal muscle dysfunction, or brown
fat tissue mass (not shown).
To further evaluate whether the ex vivo peripheral arterial
defects were also relevant in vivo, we analyzed whether
VEGF/ mice were capable of increasing cerebral blood flow
(CBF) in conditions of general oxygen shortage. Indeed,
when oxygen delivery to the brain becomes limiting, neuro-
genic constriction of resistance arteries in visceral organs
ensures that brain perfusion is increased at the expense of
peripheral organs.4 We therefore exposed anesthetized venti-
lated mice to a brief pulse of 8% oxygen (200 seconds) and
measured changes in CBF using continuous arterial spin
labeling. As expected, after the hypoxic challenge, CBF was
increased in WT mice by 33% (Figure 4B). In contrast, the
CBF in VEGF/ mice was increased by only 9% (n4;
P0.01; Figure 4B). Thus, the ex vivo documented defects in
vascular regulation of peripheral resistance arteries have in
vivo physiological consequences.
Inhibition of VEGF Impairs Vascular Regulation
in WT Mice
We then assessed whether the functional and structural defects
of arterial NEJs could also be induced on short-term inhibition of
VEGF in adult WT mice because this would provide insight into
whether VEGF might be involved in the dynamic regulation of
these junctions. We therefore hydroporated WT mice with a
plasmid encoding sFlk1, which traps VEGF, or an empty
plasmid as control. This strategy yields high plasma levels of this
VEGF inhibitor for several weeks.17 Five days after sFlk1 gene
transfer, plasma sFlk1 levels ranged from 500 to 4000 ng/mL,
sufficient to inhibit VEGF-driven tumor growth.17 Notably,
ELISA measurements, using mesenteric and saphenous arteries
after saline perfusion to remove intravascular sFlk1, revealed
that sFlk1 diffused into the arterial wall (note IV of the
online-only Data Supplement).
To evaluate the functional consequences of short-term
VEGF blockade, we analyzed whether sFlk1 gene transfer in
WT mice (sFlk1 mice) induced the same phenotypic defects
as observed in VEGF/ mice. Already 10 days after sFlk1
gene transfer, sFlk1 mice could not maintain their body
temperature on exposure to cold stress (4°C during 4.5 hours;
n9 to 12; P0.001; Figure 4C). In addition, the response of
isolated saphenous arteries to EFS was impaired in sFlk1
mice, indicating that NEJs were dysfunctional (maximal
contractile response expressed as percent of maximal re-
sponse to noradrenaline: 43.09.8% in sFlk1 mice versus
79.815.6% in controls; n7; P0.0008; Figure 4D). How-
ever, different from VEGF/ mice, contractile SMC re-
sponses to high potassium, noradrenaline, or U46619 (Figure
4E through 4G) and expression of SMC markers (Table V of
the online-only Data Supplement) were not altered in resis-
tance arteries of sFlk1 mice. Control of vascular regulation by
endothelial cells was also normal in sFlk1 mice (Figure V of
the online-only Data Supplement). Ultrastructural analysis of
mesenteric resistance arteries revealed an increase in the
distance between neuronal varicosities and SMCs by 75%
in sFlk1 arteries, as well as a reduction in the number of
varicosities per axon bundle by 30% (Table VI of the
online-only Data Supplement). The area of the varicosities
and the number of mitochondria per varicosity were not
significantly affected by sFlk1 (Table VI of the online-only
Data Supplement). Together, these results show that even
short-term treatment of adult mice with a VEGF inhibitor was
sufficient to induce functional and structural changes in
arterial NEJs without affecting SMC function.
Discussion
The present study provides genetic evidence that subnormal
VEGF levels in VEGF/ mice impair vascular regulation of
resistance arteries, thereby hindering thermoregulation and a
compensatory increase in cerebral perfusion in response to
Table 3. Ultrastructural Parameters of Perivascular NEJs
Age Artery Parameter WT VEGF/
3 mo Mesenteric Junctional cleft width 1.930.12 3.300.32*
No. of
mitochondria/varicosity
2.740.37 1.430.13*
Varicosity area 0.830.11 0.360.048*
No. of varicosities/axon
bundle
transmitter vesicle density
2.780.22 2.120.14*
13720 13427
3 mo Saphenous Junctional cleft width 1.490.045 1.900.17*
No. of
mitochondria/varicosity
2.170.24 1.510.16*
Varicosity area 0.550.083 0.260.024*
No. of varicosities/axon
bundle
3.150.19 2.360.14*
3 wk Mesenteric Junctional cleft width 0.820.065 1.140.029*
No. of
mitochondria/varicosity
3.100.45 1.940.24*
Varicosity area 0.650.080 0.320.042*
No. of varicosities/axon
bundle
4.570.46 3.290.23*
The data represent meanSEM of measurements of the distance between
nerve varicosities and SMCs (junctional cleft width in m), number of
mitochondria per varicosity, varicosity area (m2), number of varicosities per
axon bundle, and transmitter storage vesicle density (m2).
*P0.05 vs WT.
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hypoxia. Pharmacological, expression, and morphological
studies further revealed that this is due to dysfunction of
arterial NEJs and to dedifferentiation of contractile SMCs.
Moreover, short-term inhibition of VEGF in healthy mice
caused neuroeffector dysfunction without SMC defects.
Neuroeffector dysfunction was not due to overt degenera-
tion of periarterial nerves but rather to more subtle ultrastruc-
tural defects. Indeed, the junctional cleft between nerve
varicosities and target vascular SMCs was widened in
VEGF/ arteries, thereby lowering the fraction of released
neurotransmitter, reaching and activating postjunctional re-
ceptors on target SMCs, and thus impairing neuroeffector
function.21 In addition, perivascular nerves had smaller and
fewer varicosities, and these varicosities contained fewer
mitochondria. These defects may further contribute to the
impaired neuroeffector function.
Vascular SMC dysfunction in VEGF/ mice was associ-
ated with reduced levels of late vascular SMC differentiation
markers (smoothelin-B, SM-MHC), which are typically ex-
pressed by contractile arteries.19 So far, VEGF has been
shown to stimulate SMC migration and to regulate the
association of SMCs around endothelial cells22,23 but has not
been reported to regulate vascular SMC differentiation. Our
findings suggest that VEGF is required to maintain SMCs in
a fully differentiated contractile state. Whether this activity of
VEGF relies on a direct effect on SMCs or on an indirect
effect through production of “arterializing” signals from the
nerve terminal remains to be determined.
Figure 4. Impaired vascular regulation
of resistance arteries in VEGF/ or WT
mice on delivery of a VEGF trap. A, Evo-
lution of body temperature after expo-
sure of VEGF/ and WT mice to cold
stress (8°C) for 4.5 hours. B, Impaired
increase in CBF in VEGF/ mice in
response to hypoxia. C, Evolution of
body temperature of mice, hydroporated
with sFlk1 or empty (control) plasmid,
during exposure to cold stress (4°C for
4.5 hours). D, Contraction of saphenous
arteries of sFlk1 and control mice in
response to EFS. E through G,
Concentration-response curve of sFlk1
and control saphenous arteries in
response to high potassium (E), nor-
adrenaline (F), and U46619 (G). *P0.05
vs WT.
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Several mechanistic models could explain the impaired
vascular regulation of VEGF/ arteries (Figure 5). One
model, which we favor at present, postulates that reduced
release of VEGF by SMCs causes functional and structural
defects of the NEJ through direct effects on the nerve
terminal, which would secondarily cause SMC dedifferenti-
ation (“prejunctional” mechanism). Arguments in favor of
this model are that VEGF is expressed by vascular SMCs,
that VEGF levels are reduced in VEGF/ arteries, and that
VEGF receptors are expressed by periarterial nerves. A
primary neuronal defect is also suggested by findings that
neuroeffector defects are already present by 3 weeks of age,
whereas SMC differentiation is still normal. Furthermore,
sFlk1 gene transfer in adult WT mice caused structural and
functional neuroeffector changes without inducing SMC al-
terations. Previous studies documented that cultured sympa-
thetic neurons express VEGFRs and respond to VEGF by
enhanced axon outgrowth and survival,12 but so far, VEGF
has not been reported to induce structural changes in prejunc-
tional nerve terminals. Because autonomic nerve endings are
known to release SMC-trophic factors,24 a dysfunction of
these nerve terminals may secondarily lead to SMC dediffer-
entiation. Indeed, activation of 1-adrenoreceptors by nor-
adrenaline stimulates SMC proliferation,25 and sympathetic
innervation increases vascular SMC contractile protein ex-
pression,24 whereas sympathectomy results in a switch from a
contractile to synthetic SMC phenotype.26
An alternative nonexclusive model postulates that reduced
release of VEGF from nerve endings and/or vascular SMCs
could lead to SMC dedifferentiation, which would then second-
arily cause defects in neuroeffector structure and function
(“postjunctional” mechanism). Indeed, vascular SMCs are
known to promote survival of cultured postganglionic sympa-
thetic neurons.27 This model seems less likely because SMC
differentiation is normal in young VEGF/ mice and adult sFlk1
mice in which neuroeffector defects are already present. Fur-
thermore, quantitative polymerase chain reaction analysis re-
vealed that the expression of nerve growth factor, artemin, and
neurotrophin-3 (known to have plasticity effects on perivascular
autonomic nerves28) was not reduced in VEGF/ arteries. Thus,
we have little evidence to support a model whereby prejunc-
tional nerve terminals, through paracrine release of VEGF,
would ensure their own performance by inducing retrograde
release of neurotrophic cues by target SMCs. We are therefore
inclined to propose that VEGF may, at least in part, regulate the
remodeling of the NEJ through direct neurotrophic effects on the
prejunctional nerve terminals.
Short-term administration of the VEGF inhibitor sFlk1 to
healthy adult mice was sufficient to cause vascular regulation
defects and perivascular nerve dysfunction, indicating a role for
VEGF in the maintenance of NEJs. An intriguing question is
whether the observed functional and structural remodeling of the
NEJs reflects a role for VEGF in regulating the “plasticity” of
the perivascular autonomic nervous system and whether a
similar role for VEGF in regulating “synaptic plasticity” exists in
the central nervous system. Reports that VEGF stimulates
long-term potentiation in the hippocampus would be consistent
with such a model.29 These findings also raise the intriguing but
unanswered question of whether impaired vascular regulation
might explain, at least in part, the hand-foot syndrome in the
treatment of cancer patients with VEGF (receptor) inhibitors.6
Indeed, impaired vascular regulation has been proposed to
contribute to the hand-foot syndrome because dilated blood
vessels are commonly found in affected tissues,8 and decreasing
blood flow by cooling hands and feet lowers the incidence of the
hand-foot syndrome.30 Overall, our genetic and pharmacological
studies uncover a previously unrecognized role of VEGF in the
proper functioning and dynamic remodeling of perivascular
autonomic NEJs.
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CLINICAL PERSPECTIVE
Vascular endothelial growth factor (VEGF) is a key angiogenic factor, and blocking of VEGF signaling in cancer patients inhibits
angiogenesis, thereby preventing tumor progression. One of the side effects of anti-VEGF therapy is the hand-foot syndrome,
which is characterized by dilated blood vessels in hands and feet, leading to dysesthesia, erythema, and tingling of extremities,
which may progress to burning pain with dryness, cracking, and ulceration of the skin. Here, we show that knock-in mice with
reduced VEGF levels display abnormal regulation of resistance arteries, resulting in defects in thermoregulation and
redistribution of blood flow in response to hypoxia. The abnormal vascular regulation was attributed to reduced vascular smooth
muscle cell contractility associated with reduced expression of contractile proteins, as well as to dysfunction of neuroeffector
junctions as a result of their abnormal structural development. Furthermore, short-term treatment of wild-type mice with a VEGF
trap also induced thermoregulation defects and neuroeffector dysfunction with structural remodeling of neuroeffector junctions,
indicating that VEGF is necessary for maintenance of the structural and functional integrity of adult neuroeffector junctions.
These findings may provide mechanistic insights into the cause of the hand-foot syndrome.
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL METHODS 
Histology and immunohistochemistry: For whole mount staining of arteries, first order 
mesenteric and saphenous arteries were dissected and fixed in 80% MeOH/20% DMSO 
(TH staining) or in 1%PFA (VEGFR stainings) at 4°C overnight. TH staining: after 
rehydration and blocking with 2% TBS-BSA, vessels were incubated with a rabbit anti-TH 
antibody (Chemicon; 1:100) overnight. Finally, incubation with an Alexa488-labeled goat 
anti-rabbit IgG (1/200) was performed. VEGFRs staining: arteries where permeabilized 
with 0.05% Triton X-100 in PBS, blocked with 5% goat pre-immune serum and incubated 
overnight at 4ºC with antibodies against Flt1 (5µg/ml, SC-316) or Flk1 (5µg/ml, SC-504). 
Finally, 1h incubation with Alexa-labeled secondary antibodies was performed. Vessels 
were mounted on glass slides and 3D images were obtained with a Zeiss LSM510 
confocal laser scanning microscope and analyzed with Zeiss KS300 software. For analysis 
of skin vascular density, ears from 1 month old mice were dissected as described 1. The 
ears were fixed in ice cold Dent's fixative overnight and blocked with 2% TBS-BSA. For 
whole mount double immunostaining the tissues were incubated with anti-SM alpha-actin 
(Dako, 1/500) and anti-CD31 (Pharmingen, 1/500) followed by incubation with Alexa-
labeled secondary antibodies and flat-mounting. 
LacZ enzymatic staining was performed on 20 µm transverse cryo-sections of 
unfixed saphenous and mesenteric arteries. After fixation in acetone for 20 min at -20ºC, 
slides were washed in washing buffer (0.1% Sodium deoxycholate, 0.2% Nonidet P40 and 
2mM MgCl2 in PBS) and incubated overnight at 30ºC in X-gal staining solution (2mM 
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MgCl2, 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6 and 1mg/ml X-gal in PBS). Afterwards slides 
were washed in PBS, counterstained with nuclear fast red and mounted with mowiol 
(Sigma). For alkaline phosphatase (AP) binding and staining, VEGF-B186-AP and VEGF164-
AP (VEGF-AP) fusion proteins were made by cloning VEGF-B186 or VEGF164 cDNA in a 
pAPtag-5 vector (GenHunter). Fusion proteins were then expressed in HEK-293 cells as 
secreted protein, and the conditioned medium was used directly as a highly sensitive 
affinity agent. AP activity was tested via an AP-activity assay and the AP binding assay 
was performed as previously described 2. Imaging analysis was performed on a Zeiss 
Axioplan2 connected to a 3CCD video camera (DXC-93OP, Sony), and KS300 software 
(Zeiss, Germany). For the anaylsis of SMC differentiation markers and VEGF expression 
on saphenous and mesenteric arteries, arteries were dissected, fixed in 1%PFA (4ºC, 
overnight), cryo-protected and cryo-sectioned. Immunostainings were performed with the 
following antibodies: anti-smoothelin (1:100, gift of G. van Eys, Maastricht University), anti-
SM myosin HC (1:400, ab683, Abcam), anti-desmin (1:50, 10519, Cappel) and anti-VEGF 
(1/50, SC152G), followed by 2h incubation with Alexa-labeled secondary antibodies. For 
measurement of relative fluorescence intensity, arteries from VEGF∂/∂ and control mice 
were harvested and stained simultaneously, and images were acquired in random order in 
a single session. Fluorescence intensity was measured using Zeiss KS300 software with 
subtraction of background fluorescence. 
Noradrenaline content: Saphenous and mesenteric resistance artery segments, kidney 
and heart were solubilized in 0.5 M acetic acid (15 minutes, 100°C). Noradrenaline content 
of the extract was measured by high-performance liquid chromatography and fluorescent 
detection, after which the tissues were solubilized in 1N KOH (24 hours, room 
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temperature) and DNA content was determined. Noradrenaline levels were expressed 
relative to DNA content. 
Murine VEGF ELISA: For quantification of mVEGF protein expression, the Mouse VEGF 
Quantikine ELISA Kit (R&D Systems) was used. mVEGF concentrations were normalized 
to total protein concentration, which was measured using BCA assay (Pierce). 
Isometric wire myography: Two-millimeter segments of isolated first order mesenteric, 
saphenous and common carotid arteries were mounted (steel wires, diameter 40 µm) in a 
myograph organ bath (model 610, Danish Myotechnology by J.P. Trading, Denmark) for 
isometric force measurements. Organ baths were filled with a Krebs-Ringer bicarbonate 
buffer, maintained at 37°C, and aerated with 95% O2 and 5% CO2. Each individual arterial 
segment was distended to a diameter at which a maximal contractile response to 10 µM 
NA could be obtained. To evaluate SMC function, the following stimuli were used: (i) 
concentration-response curve for increasing concentrations of extracellular K+ (in 
exchange for Na+), (ii) concentration-response curve for angiotensin II (1-30 nM) during 
mild depolarization (16.5-25 mM K+), (iii) concentration-response curve for NA (0.01-10 
µM), (iv) concentration-response curve for the thromboxane A2-analogue U46619 (1-100 
nM), (v) concentration-response curve for U46619 in the continuous presence of the NO-
synthase inhibitor nitro-L-arginine (NLA, 30µM). Endothelium-dependent relaxing 
responses to acetylcholine were evaluated during contractions induced by 40 mM K+, 10 
µM NA and 100 nM U46619 and the relaxing effects of the NO-donor substance Sodium 
nitroprusside (SNP, 0.01 to 10 µM) were studied during contraction induced by U46619, in 
the presence of the NO-synthase inhibitor NLA. To evaluate perivascular sympathetic 
nerve function, the following stimuli were used: (i) response to increasing frequencies 
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(0.25-32 Hz) of electrical field stimulation (EFS) delivered by two platinum electrodes 
placed along the isolated arterial segment, (ii) concentration-response curve for increasing 
concentrations (1-100 µM) of tyramine, (iii) effect of cocaine on the arterial sensitivity to 
increasing concentrations (0.01-10 µM) of exogenous NA, (iv) addition of the alpha-
adrenoreceptor antagonist phentolamine (1 µM) on top of a maximal contractile response 
to 125 mM K+. To evaluate perivascular sensory-motor nerve function, mesenteric arteries 
were induced to contract by U46619 (0.1 µM), and the relaxing effect of either capsaicin 
(0.1 and 1.0 µM, a compound that stimulates the release of endogenous CGRP from 
sensory-motor nerves 3, 4) or exogenous CGRP (0.1 to 300 nM) was evaluated. At the end 
of the experiments, vessel segments were fixed in the organ chamber in phosphate-
buffered formaldehyde (4%, pH 7.4, 37°C, 30 minutes) for subsequent morphometric 
analysis. 
Glyoxylic acid staining: Glyoxylic acid was used to visualize and quantify perivascular 
sympathetic nerve fibers in whole mount preparations of isolated first order mesenteric and 
saphenous arteries. Vessels were mounted and stretched in an organ bath (see above) 
and incubated in 2% glyoxylic acid and 10% sucrose in phosphate buffer for 10 minutes at 
room temperature. Segments were then air dried (90 sec), stretched at 100°C for 4 
minutes and mounted on glass slides. Two-photon laser scanning microscopy was used to 
generate a stack of images from one side of the compressed vessels3, 4. The percentage 
of the area occupied by fluorescent signal was calculated. 
Noradrenaline reuptake experiments: Mesenteric and saphenous arteries were 
dissected and the length of the arterial segments was determined. Pre-incubation, 
incubation and wash steps were done in Krebs Ringer bicarbonate solution containing 
EGTA (1 mM) and glutathione (10 mM) (=KRB+ buffer), either in the absence or the 
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presence of 3 µM cocaine, an established inhibitor of NA neuronal uptake. After pre-
incubation (37°C, 30 min), 0.1 µM levo-[ring-2,5,6-3H]-NA (52.6 Ci/mmol, Perkin Elmer) 
was added to the KRB+ buffer (incubation at 37°C for 60 min). During the wash step (37°C, 
60 min), arteries were transferred repeatedly (10 times) to fresh KRB+. For extraction of 
the 3H-NA, arteries were transferred to 1 ml of 0.5 M acetic acid containing 10 mM 
glutathione, and heated at 94°C during 15 minutes. Subsequently, the artery was 
recovered and digested in 100 µl 1N KOH during 48 hours, followed by DNA content 
determination. The extract was used for liquid scintillation spectrometry. Liquid scintillation 
results (in CPM) were normalized to vessel segment length or to DNA content, and the 
difference between findings obtained in the absence and presence of cocaine was used as 
a measure of NA reuptake capacity. 
Transmission electron microscopy: Mice were anesthetized, perfused with 4% PFA and 
2.5% glutaraldehyde in Na-cacodylate buffer (0.1 M), pH 7.3 for 15 minutes. Two 
saphenous and three second order mesenteric resistance arteries were dissected from 
each mouse and fixed overnight in 4%PFA and 2.5% glutaraldehyde in Na-cacodylate 
buffer (0.1 M). The next day two rinses (2 x 30 min) with Na-cacodylate buffer (0.1 M) were 
followed by postfixation with 2% osmiumtetroxide in Na-cacodylate buffer (0.1 M) for 2h at 
room temperature. Following dehydration in a graded ethanol series (30-50-70%, each 
step 2 x 15 min) the arteries were block stained with 1% uranylacetate in 70% ethanol for 
30 min at room temperature. After the last steps of the dehydration (96-100%, each step 2 
x 15 min) the impregnation of the tissue with freshly prepared Agar 100 (EPON 812, 
Medium) was initiated by means of a graded propylene oxide – Agar 100 series (100% 
propylene oxide, 2 x 20 min – propylene oxide 1:1 Agar 100, 1 hour – propylene oxide 1:2 
Agar 100, overnight in a dessicator, room temperature). The next day the arteries were 
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transferred to freshly prepared Agar 100 and placed in a dessicator for 6 to 8 hours at 
room temperature before they were orientated in molds and put in an oven at 60° C for 48 
hours for the polymerization of the resin. Semi thin (0.5-1 µm) sections were made and 
stained with 1% toluidine blue in 1% borax for light microscopic observations. Ultra thin 
sections (70 nm) were placed on copper grids (400 mesh) and contrasted with 4% uranyl 
acetate for 10 min and lead citrate for 5 min. Ultrastructural observations were made with a 
JEOL JEM 2100 at 200 kV at the KULeuven Electron Microscopy Core Facility of the 
Department of Human Genetics, Leuven, Belgium. Light microscopic and ultrastructural 
observations were quantitatively analyzed using Zeiss KS 300 3.0 software. 
For morphometric analysis, high power electron micrographs were made of neuro-effector 
junctions in randomly selected single sections and used to measure (i) the shortest 
distance between nerve varicosities and the nearest vascular SMCs, as described 5 (ii) the 
average number of mitochondria per varicosity, (iii) the surface area of varicosities, (iv) the 
number of varicosities per axon bundle, and (v) the density of transmitter storage vesicles 
(number per varicosity/surface area varicosity), as described 6. Image acquisition and 
morphometric analysis of electron micrographs were performed by an investigator blinded 
to the mouse genotype.  
Blood flow measurements: Magnetic resonance (MR) experiments were performed on a 
7T horizontal bore magnet and 8-cm aperture self-shielded gradients with a maximum 
strength of 0.1 T/m (Oxford Instrument, UK) equipped with a MRRS console (MRRS, UK). 
Mice were anesthetized using 5% isoflurane for induction and a maintenance dose of 
0.4%-0.8% isoflurane in a mixture of O2:N2O (3:7) at a flow rate of 600 ml/min. Refined 
monitoring systems recorded body temperature (Kent, UK), breaths per minute and end-
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tidal CO2 (Capstar-100, Linton Instruments, UK), which were, respectively, 37.0 ± 0.2°C, 
180 ± 20 and 3.5 ± 0.5%. 
Arterial Spin Labeling: Continuous Arterial Spin Labeling (ASL) was used to study the 
response of CBF to hypoxia (200s at 8%O2). Single slice EPI-GE paired images were 
acquired alternately: one without arterial labelling (control image) and the other with arterial 
labelling. For each set of CBF measurements, 150 pairs of images were acquired and the 
first 4 pairs were discarded. All mice were spontaneously breathing and during ASL 
acquisition, ventilation parameters were set to hypoxic conditions by switching from 30% 
O2 to 8% O2. One trial per mouse consisted of 80 ASL measurements during normoxia, 
followed by 40 measurements during hypoxia after which recovery was allowed during 30 
measurements. Arterial spin labelling signal changes were analysed using home written 
programs in IDL (Boulder, UK), which provide regional analyses on a pixel per pixel base. 
The most straightforward approach of "simple subtraction" was used, which means direct 
pairwise subtraction between temporally adjacent label and control acquisitions. Analysis 
of the percent changes reveals whether the hypoxia induced CBF increase is present 
without the need to calculate the absolute CBF in ml/g/min. 
Purification and culture of SCG and CG neurons: SCGs and CGs from WT or VEGF∂/∂ 
P4 pups were dissected and placed in 0.25% trypsin-EDTA (Invitrogen) for 30min at 37ºC, 
washed twice with Hank’s buffered salt solution (HBSS) containing Ca2+ and Mg2+ 
(Invitrogen) and then placed in 1x collagenase in HBSS with Ca2+ and Mg2+ for 30min and 
37ºC. Ganglia were then dissociated by trituration. Neurons were finally resuspended and 
cultured in Neurobasal medium (Gibco) containing B27 (Gibco) on poly-L and laminin 
coated coverslips for 48h.  
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Table S1: Structural vessel parameters 
 
Artery Parameter WT VEGF∂/∂ 
Mesenteric Lumen diameter 166 ± 11 146 ± 17 
 Media area 2,260 ± 193 1,480 ± 258* 
 Media thickness 5.1 ± 0.6 3.1 ± 0.2* 
Saphenous Lumen diameter 221 ± 6 159 ± 6* 
 Media area 6,385 ± 460 3,720 ± 610* 
 Media thickness 8.7 ± 0.5 8.9 ± 1.0 
Carotid Lumen diameter 385 ± 20 356 ± 20 
 Media area 18,400 ± 700 15,400 ± 1,000 
 Media thickness 14.8 ± 0.4 13.3 ± 0.6 
The data represent the mean ± SEM of 5-11 measurements of the diameter of the lumen 
(µm), cross-sectional area of the media (µm2), and thickness of the media (µm). *: p < 0.05 
versus WT.  
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Table S2: Maximal contractile responses of resistance and elastic arteries 
 
Artery Stimulus 
Tension 
Stress 
WT VEGF∂/∂ 
Mesenteric 
K+ 
N/m 
N/m2 
0.88 ± 0.11 
172 ± 35 
0.14 ± 0.04* 
45 ± 15* 
 
Ang II 
N/m 
N/m2 
0.73 ± 0.04 
143 ± 46 
0.12 ± 0.05* 
38 ± 19* 
 
NA 
N/m 
N/m2 
1.41 ± 0.13 
276 ± 40 
0.31 ± 0.09* 
100 ± 32* 
 
U46619 
N/m 
N/m2 
1.28 ± 0.16 
251 ± 54 
0.29 ± 0.11* 
97 ± 46* 
Saphenous 
K+ 
N/m 
N/m2 
2.91 ± 0.31 
323 ± 46 
0.94 ± 0.54* 
105 ± 35* 
 
NA 
N/m 
N/m2 
2.92 ± 0.28 
327 ± 44 
0.96 ± 0.44* 
131 ± 49* 
 
U46619 
N/m 
N/m2 
2.57 ± 0.22 
289 ± 45 
0.79 ± 0.42* 
110 ± 52* 
Carotid 
K+ 
N/m 
N/m2 
0.58 ± 0.11 
40 ± 7 
0.52 ± 0.11 
39 ± 9 
 
NA 
N/m 
N/m2 
0.65 ± 0.08 
45 ± 6 
0.49 ± 0.09 
36 ± 6 
 
U46619 
N/m 
N/m2 
1.04 ± 0.03 
100 ± 11 
1.29 ± 0.28 
97 ± 22 
The data represent the mean ± SEM of 5-11 measurements of the maximal active wall 
tension (N/m) and wall stress (N/m2) in response to potassium (K+), angiotensin II (Ang II), 
NA (NA) or the thromboxane agonist (U46619). *: p < 0.05 versus WT.  
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Table S3: Tissue NA content   
 
Parameter Tissue WT VEGF∂/∂ 
heart 447 ± 69 455 ± 41 
kidney 86.6 ± 7.3 128.2 ± 17.1 
mesenteric artery 2,970 ± 821 4,840 ± 472 
NA content  
(pg NA/µg DNA) 
saphenous artery 2,720 ± 690 1,890 ± 147 
The values represent the mean ± SEM of 6 measurements of the noradrenaline (NA) 
content of 3 month old mice.  
 
 at UNIVERSITAIR ZIEKENHUIS BIOMED on August 2, 2010 circ.ahajournals.orgDownloaded from 
  
 11 
Table S4: Blood pressure and heart rate of VEGF∂/∂ and WT control mice. 
Parameter WT VEGF∂/∂ 
systolic BP (mmHg) 94.6 ± 9.8 90.6 ± 4.0 
diastolic BP (mmHg) 59.7 ± 9.2 68.1 ± 4.4 
MAP (mmHg) 75.7 ± 9.9 78.9 ± 4.5 
heart rate (bpm) 500 ± 25 491 ± 30 
The values represent the mean ± SEM of 5 measurements. BP: blood pressure; MAP: 
mean arterial blood pressure; bpm: beats per minute. At first sight, one might expect that 
an impairment in vasoconstrictor response, as observed in VEGF∂/∂ mice, would 
automatically result in hypotension. However, the regulation of blood pressure is a 
complex process, involving the interplay of numerous molecules. Several gene-inactivation 
studies in mice indicate that loss of even key players of vascular regulation fail to 
significantly affect the blood pressure in baseline conditions, presumably because of 
compensatory up- or downregulation of additional vasoactive substances 7-13. Alternatively, 
the defect in vascular regulation in the VEGF∂/∂ mice may be too subtle to influence 
homeostasis in baseline conditions, but sufficient to be relevant in stress conditions. 
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Table S5: Relative expression levels of smooth muscle cell differentiation markers in sFlk1 and control mice. 
Artery target gene Control sFlk1 p-value 
SM myosin heavy chain 100 ± 9.6 114.3 ± 13.7 0.40 Saphenous artery 
smoothelin 100 ± 7.9 105.8 ± 9.8 0.65 
SM myosin heavy chain 100 ± 13.7 132.9 ± 30.3 0.33 Mesenteric artery 
smoothelin 100 ± 12.5 81.4 ± 11.7 0.30 
SM myosin heavy chain 100 ± 70.3 106.7 ± 48.2 0.94 Carotid arteryA 
smoothelin 100 ± 70.0 154.9 ± 69.0 0.58 
Relative expression levels as percentage of WT ± SEM are shown. A Common carotid arteries were used. 
 at UNIVERSITAIR ZIEKENHUIS BIOMED on August 2, 2010 circ.ahajournals.orgDownloaded from 
- 13 - 
 13 
TableS6: Ultrastructural parameters of perivascular neuro-effector junctions of sFlk1 and control treated mice. 
Artery Parameter Control sFlk1 
junctional cleft width 0.85 ± 0.02 1.48 ± 0.04* 
number of mitochondria/varicosity 2.62 ± 0.29 2.75 ± 0.30 
varicosity area 0.87 ± 0.09 0.87 ± 0.11 
Mesenteric 
number of varicosities/axon bundle 3.45 ± 0.24 2.67 ± 0.24* 
The data represent the mean ± SEM of measurements of the distance between nerve varicosities and 
SMCs (junctional cleft width in µm), the number of mitochondria per varicosity, varicosity area (µm2) and 
number of varicosities per axon bundle. *: p < 0.05 
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SUPPLEMENTAL NOTES  
Note S1: VEGF protein levels in peripheral resistance arteries: pg VEGF/mg total protein: 
for saphenous arteries: 65.8±11.5 in WT mice versus 43.5±5.8 in VEGF∂/∂ mice; n=8; 
p=0.03; for mesenteric arteries: 126.3±11.3 in WT mice versus 94.8±8.2 in VEGF∂/∂ mice; 
n=8; p=0.04. VEGF protein levels in superior cervical ganglia: pg VEGF/mg total protein: 
medians (interquartile range): 96.6 (82.1-102.8) in WT mice versus 68.5 (67.1-75.0) in 
VEGF∂/∂ mice; n=8-10; Mann Whitney p-value=0.002. To ensure that these ELISA 
measurements reflected reduced VEGF expression in postganglionic neurons, ganglia 
were dissociated and neurons were cultured for 48h, followed by RNA isolation. 
Quantitative real-time PCR revealed reduced VEGF expression in VEGF∂/∂ neurons 
(relative VEGF expression: medians (interquartile range): 2.05 (1.30-2.65) in VEGF∂/∂ 
neurons versus 3.10 (2.35-3.35) in WT neurons, n=10-13; Mann Whitney p-value=0.015). 
Note S2: To analyze whether noradrenaline (NA) reuptake by perivascular nerves was 
normal, mesenteric and saphenous arteries of 2 month old VEGF∂/∂ mice were dissected 
and incubated with 3H-labeled NA in the presence or absence of the NA reuptake inhibitor 
cocaine. The NA reuptake capacity was then calculated as the difference between the 
condition with and without cocaine (see Methods for details). This approach failed to reveal 
defects in NA reuptake in mesenteric arteries of VEGF∂/∂ mice (NA reuptake in cpm/mg 
DNA: 431 ± 104 in VEGF∂/∂ mice versus 485 ± 98 in WT mice; n=10, p=0.72), as well as in 
saphenous arteries (NA reuptake in cpm/mg DNA: 407 ± 113 in VEGF∂/∂ mice versus 419 
± 89 in WT mice; n=6, p=0.93). Thus, alteration of NA reuptake by perivascular nerves 
could not explain the autonomic defects in VEGF∂/∂ mice.  
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Note S3: Thyroid function was evaluated by measuring plasma T3 and T4 hormone levels. 
No differences were found between WT and VEGF∂/∂ mice (T3 levels in ng/dl: 58.3 ± 0.88 
versus 55.3 ± 2.7 respectively in WT and VEGF∂/∂ mice, n=3, p=0.35; T4 levels in µg/dl: 
4.63 ± 0.71 versus 3.03 ± 0.29 respectively in WT and VEGF∂/∂ mice, n=3, p=0.11). 
Note S4: µg Flk1/mg protein: in mesenteric arteries: 0.24±0.08 for control versus 
0.84±0.07 for sFlk1, n=5, p=0.0005; in saphenous arteries: 0.67±0.11 for control versus 
3.21±1.08 for sFlk1, n=5, p=0.04. 
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SUPPLEMENTAL FIGURE LEGENDS 
Figure S1: Reduced VEGF expression and vascular SMC dysfunction in 
peripheral resistance arteries of VEGF∂/∂ mice. A-B, Representative pictures of 
VEGF immunostaining on mesenteric arteries from WT (A) and VEGF∂/∂ mice (B) 
showing a reduced VEGF staining intensity in VEGF∂/∂ arteries compared to WT. 
Scale bar: 5µm. C, Relative intensity of VEGF immunostaining in the SMC layer 
of mesenteric arteries, displayed as % of WT (* P=0.029, N=4). D-F, 
Concentration response curveof carotid arteries (D), mesenteric arteries (E) and 
saphenous arteries (F) of WT and VEGF∂/∂ mice in response to NA. 
Vasoconstriction is significantly reduced in mesenteric and saphenous resistance 
arteries of VEGF∂/∂ mice, but normal in carotid arteries. G-I, Even when the size 
of the vessels was taken into account (active wall stress), VEGF∂/∂ mesenteric 
and saphenous arteries exhibited a marked reduction in contractility, whereas 
contractility of carotid arteries was normal. Note that in WT mice active wall 
stress was markedly larger in the muscular mesenteric and saphenous arteries 
than in the elastic carotid artery, and that this regional difference was largely 
abolished in VEGF∂/∂ mice. *: p < 0.05 versus WT. 
Figure S2: Normal endothelial function in VEGF∂/∂ resistance arteries. To analyze 
the role of the endothelium in vascular regulation, we studied the response to 
acetylcholine (Ach), which relaxes arterial smooth muscle by inducing the release 
of endothelium-derived factors. In isolated mesenteric arteries, relaxing 
responses to increasing concentrations of acetylcholine were recorded during 
contraction induced by 20 µM phenylephrine (A,B) or high potassium (40 mM K+) 
(C,D), in the absence (A,C) or the presence (B,D) of the NO-synthase inhibitor 
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nitro-L-arginine (NLA, 30 µM). Regardless of the vasoconstrictor, a dose range of 
0.01 to 10 µM Ach induced comparable relaxations in VEGF∂/∂ and control 
arteries, indicating that vascular regulation by ECs was normal in VEGF∂/∂ mice. 
Figure S3: Reduced expression of late vascular SMC differentiation markers in 
VEGF∂/∂ arteries. A-F, Representative pictures of immunostaining for smoothelin 
(A, B), smooth muscle myosin heavy chain (C, D) and desmin (E, F) on 
saphenous arteries of WT (upper panels: A, C, E) and VEGF∂/∂ mice (lower 
panels: B, D, F). Staining intensity is reduced in VEGF∂/∂ arteries for smoothelin 
and smooth muscle myosin heavy chain, but not for desmin. Scale bar: 50µm. G, 
Relative intensity of immunostaining in the tunica media of saphenous arteries, 
displayed as % of WT. *: p < 0.05 versus WT.  
Figure S4: Neuro-effector dysfunction cannot be attributed to reduced density of 
peri-arterial nerves. To examine whether the reduced response of muscular 
arteries to neurogenic stimuli in VEGF∂/∂ mice was due to a reduced density of 
sympathetic innervation (caused by a developmental defect at 3 weeks of age, or 
by nerve degeneration at the age of 3, 6 and 12 months), we stained whole-
mount mesenteric arteries for tyrosine hydroxylase (TH), a marker of the 
perivascular sympathetic plexus. Light microscopic analysis of these whole 
mount stained vessels only allows one to visualize axon bundles of the 
autonomic plexus, but not the more subtle ultrastructural changes that can be 
observed by EM. (i) At 3 WEEKS OF AGE (i.e. after the sympathetic plexus is 
formed), a dense network of strongly stained interconnecting fibers was 
detectable over the entire surface of these vessels in both genotypes. 
Quantification of the TH-immunoreactive area as a percentage of the total vessel 
area revealed that the TH+ nervous plexus covered a similar vessel area in both 
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genotypes at 3 weeks of age (30 ± 2% in WT mice versus 28 ± 2% in VEGF∂/∂ 
mice; n=6-11, p=0.45; Figure S4A,B,E; scale bar: 25 µm), indicating that 
development of the perivascular adrenergic plexus was normal. (ii) By 3 MONTHS 
OF AGE, when vasoregulator control by perivascular nerves was dysfunctional in 
VEGF∂/∂ mice, the TH+ nervous plexus comprised 21 ± 1% in WT mice versus 27 
± 2% in VEGF∂/∂ mice (n=6-9, p=0.07). Similar findings were observed when 
analyzing the density of nerve fibers by staining with glyoxylic acid (Figure 
S4F,G). We also stained transverse sections of saphenous arteries for TH. 
Again, quantification revealed no genotypic differences in the density of 
perivascular nerves (number of perivascular nerves per section, respectively, for 
WT and VEGF∂/∂: 25.1 ± 4.6 versus 19.6 ± 2.6, n=10-14, p=0.75). Likewise, 
sensory-motor nerve dysfunction could not be attributed to nerve degeneration as 
the density of CGRP-immunoreactive nerve fibers in whole mount mesenteric 
artery preparations did not significantly differ between WT and VEGF∂/∂ (15.1 ± 
1.4% in WT mice versus 14.7 ± 1.7% in VEGF∂/∂ mice; n=8, p=0.35; Figure 
S4C,D,H; scale bar: 25µm). (iii) Also, BY 6 MONTHS OF AGE, when VEGF∂/∂ mice 
exhibit the first symptoms of motor neuron degeneration, no perivascular 
sympathetic nerve degeneration could be observed, as the TH+ nervous plexus 
comprised 28 ± 3% in WT mice and 29 ± 3% in VEGF∂/∂ mice (n=5-8, p=0.77). 
(iv) Even IN AGED, 1 YEAR OLD VEGF∂/∂ mice, the sympathetic nervous plexus was 
intact (24 ± 3% in WT mice versus 28 ± 3% in VEGF∂/∂ mice: n=6, p=0.21). Thus, 
perivascular nerve terminals are dysfunctional in VEGF∂/∂ mice, but do not show 
obvious signs of nerve degeneration, at least not at the light-microscopical level. 
Figure S5: Reduction of VEGF plasma levels in WT mice by sFlk1 does not 
impair endothelial cell function. A-D, Vasodilator response to acetylcholine (10 
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µM) during contraction induced by high potassium (40 mM) (A), NA (10 µM) (B), 
phenylephrine (10 µM) (C) and U46619 (100 nM) (D). 
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